The Netherlands Cancer Institute (NKI), the country’s leading cancer research centre, has invested in Senya Therapeutics. The NKI team, led by Dr. Christian Blank, identified a strong association between high levels of LRG1 and poor treatment response and outcomes in melanoma patients.

Building on this discovery, NKI is pursuing the development of LRG1-targeted cancer therapies and has partnered with Senya to accelerate this work. Together, NKI and Senya are now advancing anti-LRG1 therapeutic programmes across multiple tumour types, including colorectal, breast, and head and neck cancers.